Yazar "Altun, Guelay Durmus" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography(Lippincott Williams & Wilkins, 2018) Aktas, Gul Ege; Caloglu, Vuslat Yurut; Akdere, Hakan; Tutug, Busem Binboga; Altun, Guelay DurmusProstate adenocarcinoma (PCa) is the most frequently diagnosed malignancy in the male population, with the most common sites for secondary lesions being the lymph nodes, bones, and lungs. Testicular metastases from PCa are very rare and mostly identified incidentally after therapeutic orchiectomy for advanced PCa or during autopsy. Here we present a case involving a 64-year-old man with biochemical recurrence of castrated oligometastatic PCa that presented as solitary testicular metastasis on Ga-68-PSMA ligand positron emission tomography/computed tomography.Öğe Detection of regional blood flow in borderline personality disorder(Cumhuriyet Univ Tip Fak Psikiyatri Anabilim Dali, 2010) Koese, Ruguel; Abay, Ercan; Altun, Guelay DurmusObjective: To assess the role of SPECT (Single Photon Emission Computed Tomography) in the diagnosis of BPD (borderline personality disorder). Methods: Twenty BPD patients assessed with SCID-CV (Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition Axis I Disorders, Clinical Version) and had no comorbid diagnoses have been assessed with SPECT, these images were compared to the cerebral blood flow of 17 healthy individuals. The patients' SPECT images were also assessed according to the clinical data that has been gathered via SCID-II (Personality Disorders assessment of Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-Third Edition-Revised) of patients. Results: BPD patients cerebral blood flow differed from the controls' and showed corticolimbic dysfunction. Conclusion: As the dysfunction is compatible with the disorder's core symptoms, neuroimaging studies can contribute to the endophenotype studies which take into consider the clinical dimensions of BPD. (Anatolian Journal of Psychiatry 2010; 11:102-111)Öğe Melatonin administration acutely decreases the diffusing capacity of carbon monoxide in human lungs(Karger, 2006) Vardar, Selma Arzu; Altun, Guelay Durmus; Guenerbueyuek, Caner; Hatipoglu, Osman Nuri; Mert, Selva; Kaymak, KadirBackground: Most physiological measurements of the pulmonary diffusing capacity use carbon monoxide (CO) as a tracer gas. Similar to CO, melatonin binds the hemoglobin in the blood. Objective: The present study was designed to assess the effect of exogenous melatonin administration on pulmonary functions including diffusing capacity for carbon monoxide (DLCO) in healthy subjects. Methods: The study was performed in a randomized, double-blind, placebo-controlled manner. DLCO was measured in 22 healthy male volunteers ( age 18 - 25 years) who were randomized to melatonin (n = 11) and placebo administration ( n = 11). At baseline, DLCO, alveolar volume (V-A) and other spirometric parameters such as forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF) and maximal voluntary ventilation (MVV) were measured. DLCO was then corrected for the hemoglobin concentration. Measurements were repeated in a double-blind fashion 60 min after the administration of melatonin ( 1 mg) or placebo. Results: DLCO was significantly decreased (39.31 +/- 4.75 vs. 34.82 +/- 6.18 ml/min/mm Hg) 60 min after the melatonin administration ( p = 0.01), while FEV1, FVC, FEV1/FVC, PEF and MVV values did not demonstrate significant differences. Placebo administration did not result in significant alteration in any of these parameters. Conclusions: In healthy subjects, oral administration of melatonin acutely influences the DLCO without affecting other pulmonary function test results. We conclude that melatonin may have a reducing effect on the DLCO in the lungs. Copyright (C) 2006 S. Karger AG, Basel.Öğe Ziprasidone versus risperidone: Comparison of clinical efficacy and cardiac, extrapyramidal, and metabolic side effects in patients with acute exacerbation of schizophrenia and schizoaffective disorders(Kure Iletisim Grubu A S, 2009) Sonmez, Buelent; Vardar, Erdal; Altun, Guelay Durmus; Abay, Ercan; Bedel, Denizobjective: Atypical antipsychotics have different clinical side effect profiles than typical antipsychotic agents. Also, side effect profiles of atypical antipsychotic agents are different from each other. As there are no proven significant clinical superiority among atypicals other than clozapine, clinicians make their atypical choice decisions according to side effect profiles. More clinical comparison studies are needed to discern the relative efficacy and side effect profiles of atypical antipsychotics. In this study we aimed to compare clinical efficacy and extrapyramidal, metabolic, and cardiac side effects of ziprasidone and risperidone in patients with acute exacerbation of schizophrenia and schizoaffective disorders. Method: A total 22 patients diagnosed with acute exacerbation of schizophrenia or schizoaffective disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) were randomly assigned to receive ziprasidone 80-160 mg/day (n=11) or risperidone 4-8 mg/day(n=11) for 6 weeks. Positive and Negative Syndrome Scale total score (PANSS-T), positive symptoms subscale (PANSS-P) and negative symptoms subscale (PANSS-N) were used as efficacy measures. Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), were employed for movement disorder evaluations, Metabolic side effects were tested by checking laboratory tests, body weight, and body mass index measures. Electrocardiography and radionuclide ventriculography (Multigated Equilibrium Acquisition-MUGA scan) scan were used for cardiac side effect assessments. The data for twelwe patients, who complated the study were analyzed. The study was designed and conducted as a randomized open label trial. Results: Both antipsychotic drugs improved clinical symptoms significantly. The two treatment groups did not differ significantly in efficacy measures at the initial and endpoint assessments. There was statistically significant increase in parkinsonism symptoms on the 7th and 21st day evaluations in risperidone group according to SAS. Ziprasidone exhibited more beneficial effects on body weight and glucose levels. There was significant increase in prolactin levels on the 42th day lab result with risperidone, There was no difference betweeen the two drugs in terms of prolongation of QTc interval. But, ziprasidone induced more QTc prolongation on the 21st and 42th day ECGs according to baseline than risperidone. The two treatment groups did not differ significantly in left ventricular systolic and diastolic function measures at initial and endpoint assessments. Conclusions: Both drugs demonstrated significant clinical improvement. Risperidone had more extrapyramidal and endocrine side effects than ziprasidone. Ziprasidone had more QTc prolongation than the risperidone. MUGA results did not differ significantly between two groups.
